Menu
Search
|

Menu

Close
X

Medicines Co MDCO.OQ (NASDAQ Stock Exchange Global Select Market)

26.90 USD
-0.34 (-1.25%)
As of Oct 19
chart
Previous Close 27.24
Open 27.21
Volume 264,271
3m Avg Volume 284,526
Today’s High 28.14
Today’s Low 26.84
52 Week High 41.57
52 Week Low 24.45
Shares Outstanding (mil) 73.79
Market Capitalization (mil) 2,060.26
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.45 Mean rating from 11 analysts

KEY STATS

Revenue (mm, USD)
FY18
9
FY17
54
FY16
143
FY15
295
EPS (USD)
FY18
-1.892
FY17
-8.747
FY16
0.191
FY15
-2.034
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.14
Price to Sales (TTM)
vs sector
79.54
6.55
Price to Book (MRQ)
vs sector
96.96
4.00
Price to Cash Flow (TTM)
vs sector
--
21.51
Total Debt to Equity (MRQ)
vs sector
3,121.81
14.15
LT Debt to Equity (MRQ)
vs sector
3,121.81
11.31
Return on Investment (TTM)
vs sector
-26.64
12.83
Return on Equity (TTM)
vs sector
-158.61
14.95

EXECUTIVE LEADERSHIP

Clive Meanwell
Chief Executive Officer, Director, Since 2015
Salary: $896,447.00
Bonus: --
Christopher Visioli
Chief Financial Officer, Treasurer, Since 2018
Salary: --
Bonus: --
Christopher Cox
Executive Vice President, Chief Corporate Development Officer, Since 2016
Salary: $500,000.00
Bonus: --
Stephen Rodin
General Counsel, Secretary, Since 2014
Salary: $471,750.00
Bonus: --
Paris Panayiotopoulos
Director, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

8 SYLVAN WAY
PARSIPPANY   NJ   07054

Phone: +1973.2906000

The Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin). It also has a pipeline of products in development, including Carbavance, inclisiran and MDCO-700. Carbavance is used for the treatment of hospitalized patients with gram-negative bacterial infections. Inclisiran is used for the treatment of hypercholesterolemia. MDCO-700 includes sedative-hypnotic, which is used to induce and maintain sedation for procedural care and general anesthesia for surgical care. In addition to these products and products in development, it has a portfolio of generic drugs.

SPONSORED STORIES